Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019

被引:45
作者
Zhang, Yang [1 ,2 ]
Liu, Jiali [3 ]
Han, Xiao [1 ,2 ]
Jiang, Hui [1 ,2 ]
Zhang, Liming [1 ,2 ]
Hu, Juncong [1 ,2 ]
Shi, Lei [1 ]
Li, Junxiang [1 ]
机构
[1] Beijing Univ Chinese Med, Dong Fang Hosp, Dept Gastroenterol, Beijing, Peoples R China
[2] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China
[3] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China
基金
国家重点研发计划;
关键词
inflammatory bowel disease; disease burden; joinpoint regression; age-period-cohort analysis; epidemiological study; UNITED-STATES; EMERGENCY-DEPARTMENT; CROHNS; PERSPECTIVES; ASIA;
D O I
10.3389/fpubh.2022.994619
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundTo study the corresponding strategies to control inflammatory bowel disease (IBD), a comprehensive assessment of the disease burden is required. Herein, we present long-term trends in the burden of IBD in China over the last three decades, as well as its epidemiological features. MethodsWe characterized the burden of IBD in China using the GBD 2019 methods and results, based on prevalence, incidence, mortality, years lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) estimated using the DisMod-MR 2-1. We also used joinpoint and age-period-cohort (apc) analysis methods to interpret IBD epidemiological characteristics and compare them to global prevalence trends. ResultsThe age-standardized incidence and mortality rates in both sexes changed from 1.47 (95% CI: 1.24, 1.74) to 3.01 (95% CI: 2.59, 3.50) and from 0.86 (95% CI: 0.59, 1.16) to 0.30 (95% CI: 0.24, 0.35) per 100,000 people in China from 1990 to 2019. The age-standardized DALY rate in China decreased from 24.47 (95% CI: 17.88, 30.19) per 100,000 people in 1990 to 13.10 (95% CI: 10.29, 16.31) per 100,000 people in 2019. The average annual percentage change (AAPC) in age-standardized incidence, prevalence, and mortality rates for IBD in China were 2.51 (95% CI: 2.44, 2.57), 2.53 (95% CI: 2.41, 2.66), and -3.62 (95% CI: -3.85, -3.39). The effects of age, period, and cohort on incidence and mortality rates differed. ConclusionsThe increasing age-standardized prevalence rates are contributed to by the reduction in age-standardized mortality rates and DALYs, compounded by the rise in the age-standardized incidence rates between 1990 and 2019 in China. The burden of IBD in China will be a major public health challenge, given the country's large population base and aging population.
引用
收藏
页数:15
相关论文
共 43 条
  • [1] Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5
  • [2] The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
    Alatab, Sudabeh
    Sepanlou, Sadaf G.
    Ikuta, Kevin
    Vahedi, Homayoon
    Bisignano, Catherine
    Safiri, Saeid
    Sadeghi, Anahita
    Nixon, Molly R.
    Abdoli, Amir
    Abolhassani, Hassan
    Alipour, Vahid
    Almadi, Majid A. H.
    Almasi-Hashiani, Amir
    Anushiravani, Amir
    Arabloo, Jalal
    Atique, Suleman
    Awasthi, Ashish
    Badawi, Alaa
    Baig, Atif A. A.
    Bhala, Neeraj
    Bijani, Ali
    Biondi, Antonio
    Borzi, Antonio M.
    Burke, Kristin E.
    Carvalho, Felix
    Daryani, Ahmad
    Dubey, Manisha
    Eftekhari, Aziz
    Fernandes, Eduarda
    Fernandes, Joao C.
    Fischer, Florian
    Haj-Mirzaian, Arvin
    Haj-Mirzaian, Arya
    Hasanzadeh, Amir
    Hashemian, Maryam
    Hay, Simon, I
    Hoang, Chi L.
    Househ, Mowafa
    Ilesanmi, Olayinka S.
    Balalami, Nader Jafari
    James, Spencer L.
    Kengne, Andre P.
    Malekzadeh, Masoud M.
    Merat, Shahin
    Meretoja, Tuomo J.
    Mestrovic, Tomislav
    Mirrakhimov, Erkin M.
    Mirzaei, Hamed
    Mohammad, Karzan A.
    Mokdad, Ali H.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (01): : 17 - 30
  • [3] Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014
    Ballou, S.
    Hirsch, W.
    Singh, P.
    Rangan, V.
    Nee, J.
    Iturrino, J.
    Sommers, T.
    Zubiago, J.
    Sengupta, N.
    Bollom, A.
    Jones, M.
    Moss, A. C.
    Flier, S. N.
    Cheifetz, A. S.
    Lembo, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 913 - 921
  • [4] Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
    Baumgart, Daniel C.
    Le Berre, Catherine
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (14) : 1302 - 1315
  • [5] Age-period-cohort models for the Lexis diagram
    Carstensen, B.
    [J]. STATISTICS IN MEDICINE, 2007, 26 (15) : 3018 - 3045
  • [6] Perspectives of IBD China: Is Crohn's and Colitis Foundation Model a Solution to Health Care Issues for the Country?
    Chen, Yan
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (05) : 925 - 929
  • [7] Exploring Links Between Industrialization, Urbanization, and Chinese Inflammatory Bowel Disease
    Cui, Guanglin
    Liu, Hanzhe
    Xu, Gang
    Laugsand, Jann-Birger
    Pang, Zhigang
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [8] A research agenda for aging in China in the 21st century
    Fang, Evandro Fei
    Scheibye-Knudsen, Morten
    Jahn, Heiko J.
    Li, Juan
    Ling, Li
    Guo, Hongwei
    Zhu, Xinqiang
    Preedy, Victor
    Lu, Huiming
    Bohr, Vilhelm A.
    Chan, Wai Yee
    Liu, Yuanli
    Ng, Tzi Bun
    [J]. AGEING RESEARCH REVIEWS, 2015, 24 : 197 - 205
  • [9] Global age-sex, 2020, LANCET, V396, P1160, DOI [10.1016/S0140-6736(20)30977-6, DOI 10.1016/S0140-6736(20)30977-6]
  • [10] The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018
    He, Yi-Ming
    Mao, Ren
    Yuan, Gang
    Liang, Rui-Ming
    Long, Jian-Yan
    Ye, Xiao-Qi
    Iacucci, Marietta
    Ghosh, Subrata
    Ben-Horin, Shomron
    Kaplan, Gilaad G.
    He, Yao
    Sung, Joseph J. Y.
    Peng, Sui
    Wang, Hai-Bo
    Chen, Min-Hu
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15